Koya Medical Raises $30M

Home » Blog » Koya Medical Raises $30M

Venous disease and lymphedema treatment took a step forward with Koya Medical’s $30M financing. The 2020 Rosenman Innovator will continue the growth of its lymphedema treatment device, a next-generation wearable that enables movement and mobility during treatment.
From the press release:

OAKLAND, Calif. and NEW YORK, Nov. 15, 2023 /PRNewswire/ — OrbiMed, a leading healthcare investment firm and Koya Medical, a healthcare company with a mission to transform venous and lymphatic treatments through novel, people-centric solutions, today announced the closing of a financing for up to $30 million. The capital will support the company’s strategic expansion and continued growth.

“We are excited to partner with Koya on its journey to deliver innovative offerings that can help millions of patients living with these chronic conditions,” said Matthew Rizzo, General Partner, OrbiMed. “Lymphedema treatments are an underserved area for many patients, and we are just beginning to understand the full impact these diseases have on patients’ daily lives. We are pleased to have OrbiMed join us along with our existing investors on this important mission,” said Josh Baltzell, Board Chairman, Koya Medical.

With the close of this financing, Koya is well positioned to continue the growth of its Dayspring treatment for lymphedema. “Lymphedema and chronic venous diseases have tremendous unmet needs where millions of patients suffer due to the progressive nature of these conditions and their debilitating impacts. With OrbiMed joining our journey, we will be able to make a stronger impact in improving patient lives,” said Andy Doraiswamy, CEO. “This partnership and funding will enhance our abilities to better serve our patients.”